
A close reading of the 61-person NOVOS Core trial, its vascular findings, funding disclosures and the evidence still needed for longevity claims.

On November 4, 2026, University of Surrey researchers published the STAMINA trial of NOVOS Core in European Heart Journal Open. The randomized study tested a multi-ingredient nutritional powder against a matching control powder over six months.
The study's central finding was an improvement in measured vascular function among participants assigned to the supplement compared with those assigned to the control. The paper reported statistically significant adjusted differences in flow-mediated dilation, pulse wave velocity and systolic blood pressure. Its authors described the findings as preliminary and called for further evaluation. For healthspan research, the contribution is a controlled human signal that gives researchers a specific set of vascular outcomes to investigate further.
Study model: This was a human trial, not an in vitro experiment or an animal study.
According to the trial paper, researchers randomized 61 apparently healthy adults aged over 40. All were non-smokers. The supplement group included 33 participants and the control group included 28. The study was randomized, double-blind and placebo-controlled.
That design is a meaningful strength when asking whether the tested formulation affected the outcomes measured during the study. A fair reading should give the controlled design its due rather than treating the research as equivalent to a product testimonial. The important task is to identify exactly which conclusion the comparison supports.
The primary endpoint was flow-mediated dilation, usually shortened to FMD. This measures how an artery widens in response to increased blood flow. According to the paper, the adjusted difference between groups at six months favored the supplement by 2.9 percentage points.
The wording matters: this was a difference between the study groups in a defined measurement. It was not a statement that every participant experienced the same change. Reporting the result as an adjusted group difference preserves the comparison the researchers actually made.
The paper also reported differences favoring the supplement in secondary outcomes. Pulse wave velocity, abbreviated PWV, was 1.18 m/s lower. Systolic blood pressure was 6.1 mmHg lower. These figures were adjusted between-group differences at six months rather than promises about what an individual consumer would experience.
The researchers reported no significant between-group changes in the measured blood lipids. They also found a modest change in estimated 10-year cardiovascular risk that was driven primarily by the blood-pressure difference. That pattern makes the individual endpoints more informative than a broad description such as “better cardiovascular health.”
The University of Surrey's accompanying announcement likewise described the findings around vascular health biomarkers. That is an appropriate starting point for interpreting the research. The clearest account names the measurements that changed and acknowledges those that did not.
Taken together, the results give the formulation a defined research signal. The scientific value lies in having something specific to test again: the reported differences in vascular measurements under controlled conditions. That is a more useful basis for follow-up than treating the study as a general verdict on the product.
The paper identifies several reasons to keep the conclusion narrow. These affect different parts of the evidence, from who entered the analysis to what the trial was designed to establish.
For readers evaluating a longevity product, the useful first step is to identify the outcome named in the claim. A statement about FMD should be matched to the FMD result. A statement about longer life needs evidence that actually measured longer life. The point is not to dismiss an informative vascular finding but to keep the claim at the level of the evidence.
Next, check which participants entered the analysis and whether the follow-up period matches the timescale implied by the claim. Look for replication of the reported result. These questions turn a broad product description into something that can be checked against the paper without requiring the reader to accept or reject the whole field of longevity research.
This is also why the validation of aging-related measurements matters when interpreting a study. The measurement and the claim should be considered together. Likewise, following evidence from biological mechanisms toward medicine requires keeping experimental stages distinct rather than treating them as interchangeable support.
The most defensible use of this paper is to inform questions about the formulation's vascular effects and the research needed to evaluate them. Personal decisions about supplements or blood pressure belong with a qualified clinician who can consider the individual's circumstances.
The next logical phase is a larger replicated study with mechanistic measurements and longer-term clinical outcomes to test whether the reported vascular differences persist and translate into meaningful health benefits.
Interpreting NOVOS Core's vascular findings starts with classifying the outcome measured, a task AgeAmaze supports through research-led longevity reporting. Its coverage addresses the confusion created when animal lifespan findings sit beside human biomarker results, giving skeptical adults a grounded account of the evidence behind emerging interventions.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog